Pharmosa Biopharm (ROCO:6875) Current Deferred Revenue: NT$0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6875 Pharmosa Biopharm Inc ROCO:6875
27 GF Score
Price NT$33.00
GF Value NT$15.32
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Pharmosa Biopharm Current Deferred Revenue?

Pharmosa Biopharm ROCO:6875 -0.30% 27 Current Deferred Revenue is NT$0.00 Mil as of Jun. 2026. GuruFocus rates ROCO:6875 with a GF Score™ of 27/100 and a GF Value™ of NT$15.32 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Pharmosa Biopharm's current deferred revenue for the quarter that ended in Jun. 2026 was NT$0.00 Mil.

Pharmosa Biopharm Current Deferred Revenue Related Terms

Pharmosa Biopharm Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Pharmosa Biopharm's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmosa Biopharm Current Deferred Revenue Chart

Pharmosa Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Pharmosa Biopharm Quarterly Data
Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6875
27GF Score
Pharmosa Biopharm Inc ROCO:6875
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of NT$0.00 Mil mean?
Pharmosa Biopharm (ROCO:6875) has a Current Deferred Revenue of NT$0.00 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Pharmosa Biopharm and its competitors.
Is Pharmosa Biopharm's Current Deferred Revenue too high?
Pharmosa Biopharm's current Current Deferred Revenue is NT$0.00 Mil. Overall, Pharmosa Biopharm has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's Current Deferred Revenue compare to VRTX and REGN?
Pharmosa Biopharm's Current Deferred Revenue of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Pharmosa Biopharm and its competitors. Pharmosa Biopharm's current Current Deferred Revenue is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Pharmosa Biopharm (ROCO:6875) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$15.32, compared to a current price of NT$33.00 — trading 115.4% above its estimated fair value. The current Current Deferred Revenue is NT$0.00 Mil. Pharmosa Biopharm's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current Current Deferred Revenue is NT$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmosa Biopharm (ROCO:6875) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmosa Biopharm stock appears to be overvalued. The current stock price of NT$33.00 is trading 115.4% above its estimated GF Value™ of NT$15.32. GuruFocus considers Pharmosa Biopharm to be Significantly Overvalued.

Key valuation signals for ROCO:6875:

  • Current Deferred Revenue: NT$0.00 Mil
  • GF Value™: NT$15.32 vs. price of NT$33.00 (115.4% above fair value)
  • GF Score™: 27/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmosa Biopharm Business Description

Address No. 508, Sec. 7, Zhongxiao E. Road, 11th Floor / 11th Floor-1, Nangang District, Taipei, TWN
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
27GF Score

Get the complete analysis for ROCO:6875

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.00
Price
NT$15.32
GF Value